Trial Profile
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of NBP607 (Trivalent Inactivated Cell Culture-derived Influenza Vaccine) in Healthy Adults and Elderly Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2022
Price :
$35
*
At a glance
- Drugs NBP 607 (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors SK Chemicals
- 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
- 15 Mar 2015 The Ministry of Food and Drug Safety in South Korea has approved SKYCellflu, SK Chemicals' cell culture-based seasonal trivalent influenza vaccine, according to a media release.
- 28 Jan 2015 New trial record